Triple therapy may turn inoperable lung cancer into surgical candidates
NCT ID NCT07131319
First seen Feb 02, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This study tests whether a new triple therapy—spatially fractionated radiotherapy (SFRT), the immunotherapy drug tislelizumab, and standard chemotherapy—can shrink initially unresectable stage 3 non-small cell lung cancer enough to allow surgery. About 30 participants will receive this combination as induction treatment. The main goal is to see how many patients can then have their tumor surgically removed, while also monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanchang City, Jiangxi Province
RECRUITINGNanchang, Jiangxi, 330000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.